BioMarin Pharmaceutical Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 910,404
Bid Price 92.77
Ask Price 99.00
News (1)
Day High 95.43


52 Week Range


Day Low 94.14
Company Name Stock Ticker Symbol Market Type
BioMarin Pharmaceutical Inc BMRN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 95.07 00:00:12
Open Price Low Price High Price Close Price Prev Close
94.75 94.14 95.43 95.07 95.07
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15,261 910,404 $ 94.83 $ 86,334,553 - 70.73 - 97.76
Last Trade Time Type Quantity Stock Price Currency
19:56:19 75 $ 95.80 USD


Draw Mode:

BioMarin Pharmaceutical Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 17.63B 185.47M 184.65M $ 1.85B $ 55.94M -0.36 369.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -18.42k 1.10%

more financials information »

BioMarin Pharmaceutical News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BMRN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week91.9097.7691.6595.681,520,5163.173.45%
1 Month87.3197.7684.3390.231,099,5007.768.89%
3 Months79.7697.7670.7383.441,173,95215.3119.2%
6 Months90.5497.7670.7381.521,220,4214.535.0%
1 Year75.7597.7670.7382.131,280,65919.3225.5%
3 Years76.44131.94562.8883.621,397,67818.6324.37%
5 Years83.18131.94562.8885.731,316,07311.8914.29%

BioMarin Pharmaceutical Description

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

Your Recent History
BioMarin P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now